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BRIEF REPORT
Identification of BACH2 and RAD51B as Rheumatoid Arthritis Susceptibility
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Objective. A recent high-density fine-mapping
(ImmunoChip) study of genetic associations in rheuma-
toid arthritis (RA) identified 14 risk loci with validated
genome-wide significance, as well as a number of loci
showing associations suggestive of significance (P  5 
10
5 <5 10
8), but these have yet to be replicated.
The aim of this study was to determine whether these
potentially significant loci are involved in the pathogen-
esis of RA, and to explore whether any of the loci are
associated with a specific RA serotype.
Methods. A total of 16 single-nucleotide polymor-
phisms (SNPs) were selected for genotyping and asso-
ciation analyses in 2 independent validation cohorts,
comprising 6,106 RA cases and 4,290 controls. A meta-
analysis of the data from the original ImmunoChip
discovery cohort and from both validation cohorts was
carried out, for a combined total of 17,581 RA cases and
20,160 controls. In addition, stratified analysis of pa-
tient subsets, defined according to their anti–cyclic
citrullinated peptide (anti-CCP) antibody status, was
performed.
Results. A significant association with RA risk
(P < 0.05) was replicated for 6 of the SNPs assessed in
the validation cohorts. All SNPs in the validation study
had odds ratios (ORs) for RA susceptibility in the same
direction as those in the ImmunoChip discovery study.
One SNP, rs72928038, mapping to an intron of BACH2,
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3058achieved genome-wide significance in the meta-analysis
(P  1.2  10
8, OR 1.12), and a second SNP, rs911263,
mapping to an intron of RAD51B, was significantly
associated in the anti-CCP–positive RA subgroup (P 
4  10
8, OR 0.89), confirming that both are RA
susceptibility loci.
Conclusion. This study provides robust evidence
for an association of RA susceptibility with genes in-
volved in B cell differentiation (BACH2) and DNA
repair (RAD51B). The finding that the RAD51B gene
exhibited different associations based on serologic sub-
type adds to the expanding knowledge base in defining
subgroups of RA.
Rheumatoid arthritis (RA) is a complex, chronic
autoimmune disease that affects 1% of the adult
population worldwide (1). In addition to inflammation
of the synovial joints, RA is characterized by systemic
inflammation and the presence of serum autoantibodies
against citrullinated peptides (anti–citrullinated protein
antibodies [ACPAs]), as defined by positive findings on
the anti–cyclic citrullinated peptide (anti-CCP) antibody
test (2). Genome-wide association studies have been
successful in determining many loci associated with
complex diseases, including RA (3). The utility of sus-
ceptibility variants within single genetic loci, in isolation,
is likely to be limited, with evidence emerging that
linking multiple associated genes in pathways will lead to
the better understanding of differing disease mecha-
nisms (4,5). To achieve robust pathway analysis, a com-
prehensive list of associated loci must be defined. Cur-
rently, 46 loci have been confirmed to be associated with
RA susceptibility in Caucasians, at accepted levels of
genome-wide significance (P  5  10
8), including 14
loci newly identified in a recent high-density, fine-
mapping (ImmunoChip) study of RA (6).
In studies of inflammatory bowel disease (IBD),
the findings have become much more informative, im-
plicating risk pathways that have not been previously
recognized as important to this disease, and thus increas-
ing the number of susceptibility markers from 92 to 163.
The increased number of susceptibility loci for IBD has
also enabled much more informative investigation of
disease overlap. Genetic studies of RA to date, albeit
successful, have not yet delivered validated evidence of
novel pathways. Moreover, disease overlap studies have
been limited, thus emphasizing the continuing need for
discovery of disease susceptibility markers in RA.
RA is currently divided into 2 groups based on
serologic subtypes, which are defined according to the
presence or absence of anti-CCP antibodies, although it
is still unclear whether there are biologic pathways that
are common or distinct to each group (2). Determining
the genetic predisposition to each serologic subtype has
the potential to better define the mechanism underlying
each form of disease, enabling progress toward more
focused clinical management.
The most recent study aimed at identifying RA
susceptibility loci (6) used a custom Illumina array
(ImmunoChip), designed to interrogate 196,524 single-
nucleotide polymorphisms (SNPs) for 186 loci that have
been previously shown to be associated with a number of
autoimmune diseases. The study by Eyre and colleagues
was the first to be powered to analyze the subgroups of
seronegative RA and seropositive RA separately. Geno-
typing in 11,475 RA cases and 15,870 controls provided
evidence for 14 novel SNPs that achieved genome-wide
significance, with a further 16 SNPs putatively associated
with RA in a second tier of significance (P  5  10
5 
5  10
8), either in an unstratified analysis or in
stratified analyses of the anti-CCP antibody subgroups.
We therefore tested the 16 SNPs for which there was
suggestive evidence of association with RA risk in 2
independent cohorts, comprising 6,106 RA cases and
4,290 controls, and performed a meta-analysis in which
we combined our results with existing data to enhance
the power to identify associations in the whole data set
and in subgroups stratified by anti-CCP antibody status.
PATIENTS AND METHODS
ImmunoChip discovery cohort. The characteristics of
the patients in the original ImmunoChip discovery cohort
(from the UK Rheumatoid Arthritis Consortium International
[RACI]), as well as the genotyping and quality control proce-
dures used for the ImmunoChip analysis, have been previously
described (6). Individual-level data were available for each
participant, and these data were used in the present analysis.
Validation cohorts. UK cohort. The UK Rheumatoid
Arthritis Group (UKRAG) cohort of patients with RA was
recruited from 6 centers across the UK (Table 1), as previously
described (7). Genotyping was performed using the Sequenom
platform.
US cohort. Samples from patients with RA in the US
Consortium of Rheumatology Researchers of North America
(CORRONA) collection and Informatics for Integrating Biol-
ogy and the Bedside (I2B2) program were also tested using the
ImmunoChip custom genotyping SNP array (Table 1). Princi-
pal components analysis was performed using the EigenSoft
program (version 29) with HapMap phase III samples, to
exclude individuals of non-European ancestry. To check relat-
edness between the CORRONA/I2B2 samples and the RACI
ImmunoChip samples, estimates of identity-by-descent and
identity-by-state allele-sharing proportions were performed in
Plink, using a set of SNPs selected for high quality (missingness
P  0.002, minor allele frequency [MAF] 0.1) and pruned for
LD (r
2  0.2; samples were removed if the PI_HAT value was
0.2 [n  1 sample per pair]).
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lected for genotyping, based on suggestive evidence of a
significant association with RA susceptibility (P  5  10
8 to
P  5  10
5) in either the overall ImmunoChip genotyping
analysis or in subgroups defined by the presence or absence of
anti-CCP antibodies. Seven SNPs were selected from the full
ImmunoChip cohort, 5 from the anti-CCP–positive subgroup,
and 4 from the anti-CCP–negative subgroup.
Statistical analysis. Stage one: validation analysis. SNPs
were included in the validation analysis if they passed quality
control in both the UKRAG and US cohorts. Samples or SNPs
with a call rate of 98% were removed. In addition, SNPs that
did not conform to Hardy-Weinberg equilibrium (P  5 
10
7) as well as SNPs with differential missingness (P  0.01)
or an MAF 0.01 were also removed. After applying all of the
quality control filters, 4 SNPs (from 944 RA cases [20%] and
244 controls [9%]) failed quality control.
We tested for the association of each SNP with RA in
each study independently, using logistic regression under an
additive model, and then combined the results in a fixed-
effects meta-analysis with inverse variance weighting (per-
formed in Plink). The top 10 principal components were
incorporated as covariates in the logistic regression analysis of
the US CORRONA data set, to correct for population strati-
fication. P values less than 0.05 were considered as evidence of
a significant association in the validation cohorts.
Stage two: meta-analysis of ImmunoChip and validation
data. The association of each SNP with RA in the original
ImmunoChip analysis and in the validation analysis was tested
in a fixed-effects meta-analysis with inverse variance weighting
(performed in Plink). A Pmeta-analysis threshold of less than 5 
10
8 was considered significant, i.e., indicative of the discovery
of a novel RA risk gene. All P values reported are 2-tailed.
Heterogeneity between studies was assessed using Cochran’s
Q statistic test and the I
2 test. A P value for heterogeneity of
less than 0.05 is suggestive of heterogeneity. The I
2 test
estimates the extent of heterogeneity and takes values between
0% and 100%. I
2 values of 0–25% indicate low heterogeneity,
25–50% moderate heterogeneity, 50–75% high heterogeneity,
and 75–100% extreme heterogeneity (8).
Anti-CCP subset analysis. In separate analyses of the
data from the validation study and the data from the meta-
analysis, we compared associations of all SNPs between con-
trols and either anti-CCP–positive or anti-CCP–negative RA
patients. In the validation study, there were 1,946 anti-CCP–
positive RA patients, 720 anti-CCP–negative RA patients, and
4,290 controls. For the meta-analysis, there were 9,169 anti-
CCP–positive RA patients, 4,059 anti-CCP–negative RA pa-
tients, and 20,160 controls.
Power calculations. All power calculations were under-
taken using Quanto. The model assumed was a log additive
model, and population baseline risk estimate was 1%.
RESULTS
In the validation analysis, 6 loci showed an asso-
ciation with RA susceptibility that reached significance
(P  0.05): COG6, PVT1, PTPN2, TNFSF4, RAD51B,
and BACH2 (Table 2). In the meta-analysis, 2 SNPs
achieved genome-wide significance levels (Pmeta-analysis
 5  10
8): BACH2 in the full meta-analysis (Figure
1A), and RAD51B in the anti-CCP–positive subgroup
(Figure 1B). These findings in the meta-analysis indicate
that BACH2 and RAD51B are novel validated RA risk
alleles. For the remaining SNPs, all effect sizes were in the
same direction as in the original ImmunoChip analysis.
In the meta-analysis, 1 SNP, rs7535176, showed
evidence of high heterogeneity between studies (I
2 
57%), and was therefore removed from further analysis.
In power calculations, the average power to detect the
likelihood of an association with RA at an OR of 1.12
(P  5  10
8) was 81% in the overall validation study,
Table 1. Distribution of rheumatoid arthritis (RA) cases and controls in the ImmunoChip discovery
cohort and the 2 validation cohorts*
Collection
RA cases Controls
All
Female,
%
Anti-CCP
positive
Anti-CCP
negative All
Female,
%
ImmunoChip
US 2,536 75 1,803 593 2,134 65
Swedish EIRA 2,762 70 1,762 987 1,940 73
Swedish Umea 852 70 524 242 963 69
Dutch 648 66 330 301 2,004 42
Spanish 807 74 397 216 399 65
UK 3,870 74 2,406 1,000 8,430 53
Total 11,475 72 7,222 3,339 15,870 61
Validation
CORRONA/I2B2 (US) 2,206 78 1,410 446 1,863 75
UKRAG (UK) 3,900 73 536 274 2,427 74
Total 6,106 76 1,946 720 4,290 75
Combined 17,581 73 9,168 4,059 20,160 65
* Except where indicated otherwise, values are the number of participants. Anti-CCP  anti–cyclic
citrullinated peptide; EIRA  Epidemiological Investigation of Rheumatoid Arthritis; CORRONA 
Consortium of Rheumatology Researchers of North America; I2B2  Informatics for Integrating Biology
and the Bedside; UKRAG  UK Rheumatoid Arthritis Group.
3060 MCALLISTER ET AL41% in the anti-CCP–positive RA subset, and 6% in the
anti-CCP–negative RA subset, based on an average
MAF of 0.19.
DISCUSSION
Of the 12 loci assessed for an association with
susceptibility to RA in the validation study, 2 reached
accepted genome-wide significance thresholds either in
the RA group as a whole or in the subset with anti-CCP
antibodies, indicating that these 2 loci (BACH2,
RAD51B) represent novel RA susceptibility loci. A
further 4 SNPs showed evidence for validation of an
association at a significance level of P  0.05 (COG6,
PVT1, PTPN2, and TNFSF4). All of the loci assessed
showed effect sizes in the same direction as those in the
original ImmunoChip discovery study. Of the newly
confirmed RA susceptibility SNPs, rs72928038 maps to
an intron of BACH2 (6q15), which has previously been
associated with type 1 diabetes (9), Crohn’s disease (10),
and celiac disease (11). BACH2 encodes BTB and CNC
homology 1, basic leucine zipper transcription factor 2, a
B cell–specific transcription factor that has been shown
to regulate the BLIMP1 gene (also known as PRDM1,a
validated RA susceptibility locus) in mice, which in turn
influences plasma cell differentiation and promotes the
antibody class switch (12). Rituximab, an effective RA
treatment, inhibits CD20 B cells, a cell subtype in
which BACH2 is highly expressed.
The second novel SNP associated with RA,
rs911263, was found to be significantly associated
with RA risk in the anti-CCP–positive subgroup
(Panti-CCP meta-analysis  4  10
8) but not in the
anti-CCP–negative subgroup (Panti-CCP meta-analysis 
0.45). This SNP maps to an intron in RAD51B (14q24),
which has recently been found to be associated with
primary biliary cirrhosis (13). RAD51B is a gene in-
Figure 1. Forest plots of the association of rheumatoid arthritis (RA) susceptibility with the 2 single-nucleotide polymorphisms showing
genome-wide significance, BACH2 (A) and RAD51B (B), in the meta-analyses. Results are presented as the odds ratio (OR) with 95% confidence
interval (95% CI) for the overall meta-analysis and for the subgroups of anti–citrullinated protein antibody–positive (ACPAve) RA and
anti-ACPA–negative (ACPA-ve) RA (determined by anti–cyclic citrullinated peptide test). The meta-analyses are based on a fixed-effects model.
Table 2. Associations of single-nucleotide polymorphisms (SNPs) with rheumatoid arthritis susceptibility in the ImmunoChip discovery cohort,
validation cohorts, and meta-analysis*
ImmunoChip Validation
Meta-analysis
Anti-CCP Anti-CCP
Chr SNP
Position
(hg19) Gene
Minor
allele
Study
P
Study
OR
Study
P†
Study
OR
Study
P
Study
OR P OR P OR
1 rs61828284‡ 173,299,743 TNFSF4 A 5.5  10
6 0.83 0.01 0.81 1.5  10
5 0.88 2.1  10
7 0.82 0.48 0.97
2 rs888427§ 172,368,120 CYBRD1 A 5.2  10
5 1.12 0.76 1.02 0.00021 1.06 0.017 1.05 1.6  10
4 1.1
3 rs1875463¶ 143,165,502 SLC9A9 A 1.5  10
6 0.90 0.69 0.99 2.0  10
5 0.92 1.2  10
4 0.92 8.7  10
5 0.89
6 rs72928038¶ 90,976,768 BACH2 A 8.2  10
7 1.13 0.004 1.11 1.1  10
8 1.12 8.5  10
6 1.12 2.5  10
4 1.13
7 rs59472144¶ 37,369,908 ELMO1 A 3.5  10
6 1.12 0.78 1.01 5.1  10
5 1.09 9.3  10
5 1.10 0.04 1.07
8 rs6651252¶ 129,567,181 PVT1 G 2.0  10
5 0.89 0.004 0.88 2.4  10
7 0.89 5.3  10
5 0.89 0.001 0.88
9 rs7857530§ 102,747,941 TXNDC4 G 2.5  10
5 0.89 0.94 1.00 0.022 0.96 0.40 0.98 1.7  10
4 0.91
13 rs7993214‡ 40,350,912 COG6 A 4.6  10
6 0.90 0.05 0.92 9.1  10
7 0.92 6.0  10
7 0.9 0.15 0.96
13 rs17230016¶ 82,338,338 SPRY2 G 9.6  10
6 0.88 0.56 0.97 4.7  10
5 0.91 0.003 0.92 0.001 0.88
14 rs911263‡ 68,753,593 RAD51B G 2.3  10
6 0.89 0.005 0.88 4.0  10
5 0.93 4.0  10
8 0.89 0.44 0.98
17 rs8074003¶ 76,364,493 SOCS3 A 1.4  10
5 0.81 0.44 0.95 9.2  10
5 0.86 1.9  10
3 0.86 9.2  10
4 0.80
18 rs62097857¶ 12,857,758 PTPN2 A 4.5  10
6 1.22 0.01 1.20 1.4  10
7 1.22 3.9  10
6 1.23 6.2  10
5 1.26
* Association analyses of SNPs were performed using case and control data from the original ImmunoChip discovery cohort, the validation cohorts
(UK and US), and the meta-analysis (ImmunoChip and validation cohorts). OR  odds ratio.
† Validation P value is presented for each SNP in the same stratification as that in the discovery study.
‡ Anti–cyclic citrullinated peptide (anti-CCP)–positive RA subgroup.
§ Anti–CCP–negative RA subgroup.
¶ Full RA group.
ASSOCIATION OF BACH2 AND RAD51B WITH RA 3061volved in the homologous recombination repair pathway
of double-stranded DNA breaks. It has been demon-
strated that anti-CCP–positive and anti-CCP–negative
disease have differing allelic associations at the HLA
locus, and identification of an association of RAD51B
with anti-CCP–positive RA may add to the list of genes
that differentiate between the disease subgroups, al-
though this could not be formally proven in the present
study because of the reduced power in the anti-CCP–
negative cohort.
An association of 4 loci (COG6, PVT1, PTPN2,
and TNFSF4) with RA risk was replicated in the valida-
tion study, at P  0.05, but none reached genome-wide
significance in the overall analysis. Given that these loci
are associated with multiple autoimmune diseases, there
is strong a priori evidence that these are likely to be RA
susceptibility loci. Indeed, an association of RA risk with
PTPN2 has now reached genome-wide significance lev-
els, as demonstrated in an expanded, independent ana-
lysis in a European cohort (14).
The number of SNPs with suggestive evidence
from the ImmunoChip analysis suggests that there are
many additional undiscovered risk alleles with modest
effect sizes that have yet to be formally confirmed at
genome-wide significance levels of association. Power
calculations showed the necessity of larger sample sizes
to detect the more modest effect sizes detected in this
second tier of significance, indicating that there is still
great value in increasing study size to identify novel
susceptibility loci. Indeed, combined sample sizes of
more than 75,000 cases and controls were required to
identify the 163 loci now confirmed to be associated with
IBD. Sample size and power therefore remain a limita-
tion in our current study, in particular with respect to the
lack of data on the ACPA status of patients in the
validation cohorts. A further limitation in this study was
the targeted SNP genotyping, chosen as a cost-effective
strategy to confirm putative associations. By adopting
this strategy, our capacity to fine map the newly identi-
fied loci was restricted to data generated in the Immu-
noChip experiment.
In conclusion, we obtained convincing evidence
of 2 new RA susceptibility loci, BACH2 and RAD51B,i n
a combined meta-analysis of 17,581 cases and 20,160
controls, bringing the total number of novel RA suscep-
tibility loci identified in Caucasians to 48. These findings
implicate 2 distinct biologic pathways, those of B cell
differentiation and DNA repair, in serologic subtypes of
RA. Identification of all genetic variants that predispose
to RA will increase our understanding of the molecular
mechanisms involved and better annotate biologic path-
way analyses.
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